AUPH - CIK 0001600620
The table below shows Aurinia Pharmaceuticals Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $40.75M | $72.89M | $52.91M | $66.11M | $36.63M | $33.27M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | $46.41M | $44.79M | $46.50M | $46.20M | $38.71M | $38.85M |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $480.24M |
| $438.74M |
| $408.97M |
| $405.76M |
| $440.46M |
| $409.67M |
| Property, plant & equipment | $1.99M | $2.27M | $2.42M | $2.58M | $2.89M | $3.04M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $724.00M | $527.53M | $502.56M | $504.85M | $549.36M | $523.53M |
| Accounts payable | $2.66M | $2.21M | $3.31M | $4.22M | - | - |
| Total current liabilities | $86.56M | $76.22M | $78.27M | $68.41M | $78.61M | $76.90M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $156.37M | $161.76M | $167.26M | $154.66M | $161.36M | $158.91M |
| Retained earnings | -$615.01M | -$860.16M | -$891.71M | -$913.23M | -$938.00M | -$952.35M |
| Total equity | $567.63M | $365.77M | $335.30M | $350.19M | $388.00M | $364.62M |